Cytek Biosciences: Q2 2025 Financial Performance Overview

Cytek Biosciences, Inc. ( (CTKB) ) has released its Q2 earnings. Here is a breakdown of the information Cytek Biosciences, Inc. presented to its investors.

Cytek Biosciences, Inc., headquartered in Fremont, California, is a leading company in the cell analysis solutions sector, known for its Full Spectrum Profiling technology that enhances cell analysis through high-resolution and high-sensitivity tools.

In its second quarter of 2025 financial report, Cytek Biosciences announced a total revenue of $45.6 million, marking a slight decrease of 2% compared to the same period in 2024. Despite this, the company has shown resilience with growth in its recurring revenue streams and the launch of a new product, the Cytek Aurora Evo system.

Key financial highlights include a 3% increase in the installed base of its instruments and a 16% growth in recurring revenue from services and reagents. However, the company faced a net loss of $5.6 million, an improvement from the previous year’s loss of $10.4 million. Operating expenses saw a slight increase, with notable growth in general and administrative costs.

Strategically, Cytek has focused on innovation and market expansion, highlighted by the launch of the Cytek Aurora Evo system, which promises enhanced performance and efficiency. The company also repurchased $4.5 million of its common stock, indicating confidence in its long-term value.

Looking ahead, Cytek Biosciences remains optimistic about its growth prospects, aiming to expand its global installed base and increase recurring revenue. The company anticipates a revenue range of $196 million to $205 million for the full year 2025, reflecting a potential growth of -2% to +2% over 2024, as it continues to navigate a challenging macroeconomic environment.